8 completed, 1 recruiting, 1 terminated, 1 withdrawn. 7 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 2 | 5 | Completed 3, Recruiting 1, Withdrawn 1 |
Follow ICG 001: new trials by email Literature Review of ICG 001 trials Research Report on ICG 001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia Foscenvivint - Liver Cirrhosis | Phase 2 | Recruiting | Kiminori Kimura, MD | 7 | 2026-10-01 | 2026-10-05 |
| A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201) Foscenvivint - Liver Cirrhosis | Phase 2 | Completed | Kiminori Kimura, MD | 5 | 2024-05-08 | 2026-05-01 |
| Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia. OP-724 - Liver Cirrhosis | Phase 1 | Completed | Kiminori Kimura, MD | 5 | 2021-03-15 | 2024-10-21 |
| Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) OP-724 - Primary Biliary Cholangitis (PBC), Liver Cirrhosis, Biliary | Phase 1 | Completed | Kiminori Kimura, MD | 7 | 2019-08-29 | 2022-07-07 |
| Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis PRI-724 - Hepatitis C, Hepatitis B | Phase 1 / Phase 2 | Completed | Kiminori Kimura, MD | 27 | 2018-07-24 | 2024-10-10 |
| Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer CBP/beta-catenin Antagonist PRI-724, Bevacizumab, Leucovorin Calcium - Colorectal Adenocarcinoma, Stage IVA Colorectal Cancer | Phase 2 | Withdrawn | University of Southern California | 2015-11-01 | 2017-04-17 | |
| A Follow-up Evaluation Study of PRI-724-1101 PRI-724 - Hepatitis C Virus-infected Cirrhosis | Completed | Komagome Hospital | 8 | 2014-12-18 | 2022-07-07 | |
| An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis PRI-724 - Hepatitis C Virus-infected Cirrhosis | Phase 1 | Completed | Komagome Hospital | 14 | 2014-08-01 | 2022-07-07 |
| Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma PRI-724 - Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 | Completed | Prism Pharma Co., Ltd. | 20 | 2013-04-01 | 2017-08-17 |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies PRI-724 - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Prism Pharma Co., Ltd. | 49 | 2012-07-01 | 2017-08-17 |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors PRI-724 - Advanced Solid Tumors | Phase 1 | Terminated | Prism Pharma Co., Ltd. | 23 | 2011-02-01 | 2017-08-17 |
Liver Cirrhosis (4) · Hemophilia A (3) · Hepatitis C (2) · Pancreatic Neoplasms (2) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Fibrosis (1) · Hepatitis B (1) · Leukemia (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Liver Cirrhosis, Biliary (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Kiminori Kimura, MD (5) · Prism Pharma Co., Ltd. (3) · Komagome Hospital (2) · University of Southern California (1)
Japan (7) · United States (4)
Kiminori Kimura, MD (7) · Anthony El-Khoueiry, MD (1) · Heinz-Josef Lenz (1) · Jorge Cortes, MD (1) · Robert R. McWilliams, M.D. (1)
PMID 28844410, PMID 35605429, PMID 36442892, PMID 38677720
P30CA014089 (1), R01CA166161 (1)